The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic ...

According to a statement from the agency on Thursday, Lumakras, also known as sotorasib, will be indicated in the U.S. with Amgen’s (NASDAQ:AMGN) epidermal growth factor receptor (EGFR ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300, a phase 3 ...

M.D., executive vice president of Research and Development at Amgen. 2 "LUMAKRAS plus Vectibix offers a targeted, biomarker-driven combination therapy that helps delay disease progression more ...

Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

The U.S. Food and Drug Administration (FDA) has approved Amgen’s (NASDAQ:AMGN) KRAS G12C inhibitor Lumakras as part of a combination regimen for adults with metastatic colorectal cancer (mCRC ...

Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® (panitumumab ...

About LUMAKRAS®/LUMYKRAS® (sotorasib) LUMAKRAS received accelerated approval from the FDA on May 28, 2021. The FDA completed its review of Amgen's supplemental New Drug Application (sNDA ...